Laura Stoppel, Ph.D.
Laura Stoppel Ph.D., is a Principal on the Investment Team at RA Capital Management. Dr. Stoppelworks on both public and private investments and serves as a Board Director for Nimbus Therapeutics and Acumen Pharmaceuticals, and as a Board observer for Vor Biopharma. Previously, Dr. Stoppel covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Dr. Stoppel holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.